Biotech News
Related news
IMTXImmatics2026-10-24 06:30 EST
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
LYELLyell Immunopharma2026-11-04 14:02 EST
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
NRIXNurix Therapeutics2026-09-29 11:00 EST
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Immatics
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...
Recent company news
IMTXImmatics2026-10-24 06:30 EST
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
IMTXImmatics2026-08-25 11:00 EST
Immatics Announces $150 Million Underwritten Offering
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IMTXImmatics2026-06-01 12:00 EST
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Stock data
- Close
- 6.18 USD
- Market cap
- 1.37B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States